| Abstract |
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses. |
| Authors | Sarah E Kleinstein, Patrick R Shea, Luisa M Stamm, Mark Sulkowski, David B Goldstein, Susanna Naggie |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 66
Issue 12
Pg. 1953-1956
(06 01 2018)
ISSN: 1537-6591 [Electronic] United States |
| PMID | 29522085
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Alkynes
- Antiviral Agents
- Benzimidazoles
- Benzoxazines
- Cyclopropanes
- Fluorenes
- ledipasvir
- CYP2B6 protein, human
- Cytochrome P-450 CYP2B6
- efavirenz
- Sofosbuvir
|
| Topics |
- Black or African American
- Alkynes
- Antiviral Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Benzoxazines
(blood, metabolism)
- Cohort Studies
- Coinfection
(drug therapy, ethnology, virology)
- Cyclopropanes
- Cytochrome P-450 CYP2B6
(genetics)
- Drug Therapy, Combination
- Female
- Fluorenes
(therapeutic use)
- Genome-Wide Association Study
- Genotype
- HIV Infections
(drug therapy, ethnology)
- Hepacivirus
(drug effects)
- Hepatitis C
(drug therapy, ethnology, genetics)
- Humans
- Male
- Polymorphism, Single Nucleotide
- Recurrence
- Sofosbuvir
(therapeutic use)
|
